News from the web:

Avraham Pharmaceuticals Ltd.The interim report on ladostigil’s safety profile found no serious or exceptional side effects, so the trial can continue from the safety aspect. The interim results also showed a positive trend in the drug’s efficacy. The interim results are based on 179 patients, 66 of whom have undergone six months of therapy. The company added that the number of patients planned for the study was enough to provide statistically meaningful final results, and the expert panel therefore recommends pursuing the study. The company expects to complete the trial and obtain the results by the end of the year.

Read all about it HERE

News from the web:

A SWINDON research centre is taking part in a global study of an experimental drug to treat a form of Alzheimer’s disease.

Prodromal AD is a condition in which a person’s memory loss is worse than can be expected by the normal ageing process alone, even though their ability to get on with daily activities is not affected to such an extent that they would be diagnosed with dementia.

In the past, people with the condition would have been considered to be showing symptoms of old age but it is now becoming more recognised.

The Kingshill Research Centre is taking part in the Scarlet Road Study, which is taking place in approximately 100 centres in about 15 countries, with about 360 people required to take part.

Read all about it HERE

News from the web:

Pfizer and Medivation ended their collaboration on the experimental drug Dimebon for Alzheimer’s disease after the medicine failed in another late-stage clinical trial.

Dimebon was one of two drugs Pfizer had in its late-stage pipeline to treat the neurodegenerative disease. The other is bapineuzumab, which Pfizer is developing with Johnson & Johnson. The treatments have different mechanisms of action.

Dimebon didn’t show statistically significant results in a study that evaluated the compound when added to a standard treatment in patients with mild to moderate forms of the disease, the companies said Tuesday. The companies will end development of the drug for all uses, and will stop a current study.

Read all about it HERE